<DOC>
	<DOCNO>NCT02227550</DOCNO>
	<brief_summary>Study objective demonstrate anticoagulation direct factor Xa inhibitor apixaban less safe Vitamin-K-antagonists ( VKA ) therapy patient undergoing catheter ablation non-valvular AF prevention peri-procedural complication . The AXAFA trial compare peri-ablational treatment apixaban peri-ablational treatment wit VKA randomize trial patient undergoing catheter ablation atrial fibrillation ( AF ) .</brief_summary>
	<brief_title>Apixaban During Atrial Fibrillation Catheter Ablation : Comparison Vitamin K Antagonist Therapy</brief_title>
	<detailed_description>AXAFA open-label trial design evaluate safety efficacy two type anticoagulant therapy , VKA therapy therapy direct factor Xa inhibitor apixaban , patient undergo schedule catheter ablation AF . All patient undergo ablation procedure pre-treatment anticoagulant ( either apixaban `` Xa group '' vitamin K antagonist `` VKA group '' ) . Patients undergo catheter ablation within trial least 30 day continuous effective anticoagulation . Ablation perform earlier timely exclusion atrial thrombus exclude clinically indicate transthoracic echocardioggram ( TEE ) . After TEE continuous effective anticoagulation must ensure end trial . In MRI-substudy explore wether novel oral anticoagulant ( NOAC ) potential reduce clinically silent brain lesion catheter ablation AF .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>I1 . Nonvalvular AF ( ECGdocumented ) clinical indication catheter ablation I2 . Clinical indication undergo catheter ablation continuous anticoagulant therapy I3 . Presence least one CHADS2 stroke risk factor Stroke TIA age ≥ 75 year , hypertension , define chronic treatment hypertension , estimate need continuous antihypertensive therapy rest blood pressure &gt; 145/90 mm Hg , diabetes mellitus , symptomatic heart failure ( NYHA ≥ II ) . I4 . Age ≥ 18 year I5 . Provision sign informed consent General exclusion criterion E1 . Any disease limit life expectancy le 1 year E2 . Participation another clinical trial , either within past two month still ongoing E3 . Previous participation AXAFA E4 . Pregnant woman woman childbearing potential adequate birth control : woman highly effective method contraception ( oral contraception intrauterine device ) sterile woman randomise . E5 . Breastfeeding woman E6 . Drug abuse clinically manifest alcohol abuse E7 . Any stroke within 14 day randomisation Exclusion criterion related cardiac condition E8 . Valvular AF ( define focus update ESC guideline AF , i.e . severe mitral valve stenosis , mechanical heart valve ) . Furthermore , patient underwent mitral valve repair eligible AXAFA . E9 . Any previous ablation surgical therapy AF E10 . Cardiac ablation therapy indication ( catheterbased surgical ) within 3 month prior randomisation E11 . Clinical need `` triple therapy '' ( combination therapy clopidogrel , acetylsalicylic acid , oral anticoagulation ) E12 . Other contraindication use VKA apixaban Exclusion criterion base laboratory abnormality E13 . Severe chronic kidney disease estimate glomerular filtration rate ( GFR ) &lt; 15 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Atrilal fibrillation</keyword>
	<keyword>anticoagulation</keyword>
	<keyword>prevention peri-procedural complication</keyword>
	<keyword>catheter ablation</keyword>
</DOC>